Answers are grounded in this paper and cite their sources.
Author correspondence clarifies methodological considerations for evaluating real-world durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, highlighting robust analytical design.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tada et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: